Developer docs
API playgroundTry for free, no card

Search company profiles

SEQUENTIAL

Full company profile

uuid0002b88

Namestring
SEQUENTIAL
Legal namestring
Sequential Skin Ltd
Websiteurl
sequential.bio
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Sequential (legally Sequential Skin Ltd) is a London-headquartered skin microbiome testing company founded in 2019 that operates end-to-end clinical research services for the dermocosmetics, pharmaceutical, clinical research organization (CRO), and ingredient manufacturing industries. The company's core offering is a multi-omics platform combining microbiome sequencing (16S, ITS, shotgun metagenomics), proprietary qPCR Smart Probes, and bioinformatics to characterize the impact of skincare and therapeutic products on the human skin microbiome in vivo, supported by a proprietary database of 50,000+ skin microbiome samples linked to 4,000+ ingredient interactions and a non-invasive patch-based sample collection system (Sequential Patch). Modular add-ons include biophysical clinical assessments, condition-specific targeted panels (e.g., Sun/UV Panel), ingredient testing, participant recruitment, and white-label consumer test kits for commercial partners.

The business generates revenue primarily through professional services B2B contracts for clinical studies, supplemented by hardware/white-label consumer test kit partnerships (e.g., Gallinée) and consumer product lines such as the Biome Mask. Pricing is quote-based and not publicly disclosed, reflecting enterprise sales motion targeting large dermocosmetics brands, pharma therapeutics developers, CROs, and ingredient suppliers. The company operates labs in Cambridge (UK), New York City (US, via J&J JLABS Innovation NYC residency), and Singapore (supported by A*STAR and Enterprise Singapore), giving it a tri-regional UK-US-APAC footprint. Named commercial partners include Johnson & Johnson, Curive Healthcare, Gallinée, and Symbiome, with 100+ industry partners and 10,000+ study participants cumulatively enrolled across clinical studies. Sequential has raised approximately $7.5M in cumulative equity and grant funding, including a $1.65M seed round (October 2021), Innovate UK and A*STAR grants, a $1.8M UK-Singapore R&D grant (February 2025), and a $3.5M equity round (March 2026) co-led by Corundum Systems Biology and Sparkfood, with the most recent capital earmarked for an AI-Powered Discovery Engine launched alongside the financing.

Short descriptiontext

Sequential is a London-based skin microbiome testing company that provides B2B multi-omics clinical research services, including microbiome sequencing, qPCR Smart Probes, and bioinformatics, to dermocosmetics brands, pharmaceutical companies, CROs, and ingredient manufacturers across the UK, US, and Singapore.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
skin microbiome testing, clinical research services, multi-omics analysis, dermatology clinical trials, ingredient validation testing
Industry3 codes
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Microbiome Testing & Clinical Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1B2B Clinical Testing Services
TypeProfessional Services
Description

Sequential generates revenue primarily through providing contract clinical testing services to dermocosmetics brands, pharmaceutical companies, CROs, and ingredient manufacturers. Services include microbiome analysis, biomarker testing, and multi-omics characterization of skin health outcomes from product usage in human clinical studies.

2White-Label Consumer Testing Kits
TypeHardware Sales
Description

Sequential offers white-label at-home skin microbiome test kits to commercial partners, enabling brands to provide direct-to-consumer microbiome analysis services under their own brand.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1Sequential Bio
Description

The company's testing and discovery platform serving consumer goods, biotech, and pharmaceutical companies for skin microbiome analysis.

sequential.bio
+4 more records
Core offering1 text field

Sequential (operating as Sequential Skin Ltd) provides end-to-end in-vivo clinical testing and multi-omics analysis services for the personal care, pharmaceutical, and clinical research industries, specializing in skin microbiome characterization. The company integrates study design, participant recruitment, non-invasive sample collection, laboratory analysis (microbiome sequencing, qPCR, genomics, proteomics), and claim-ready reporting for dermocosmetics brands, pharma therapeutics developers, CROs, and ingredient manufacturers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Database of 50,000+ skin microbiome samples
+3 more records
Product overview1 text field

Sequential operates a unified end-to-end clinical research platform for skin, scalp, oral, and intimate care, combining human in-vivo testing with a multi-omics analysis engine to quantify product and ingredient impact on skin and the microbiome. The platform is organized as a core testing platform supported by modular services: Microbiome Testing and Multi-Omic Studies form the analytical foundation, Clinical Assessments and Biophysical Measurements serve as add-on testing modules, Ingredient Testing Services and Targeted Microbiome Panels (including the Sun/UV Panel with Smart Probes qPCR) extend to specific use cases, and Consumer Kits and the Skin Health Tracker App address the direct-to-consumer segment. The Biome Mask is a separate consumer product line. The company also announced an AI-Powered Discovery Engine (March 2026) leveraging 50,000+ samples and 4,000+ ingredients to power predictive ingredient discovery. Labs are located in Cambridge, New York City, and Singapore.

Product and service10 records
1Sequential End-to-End Clinical Testing Platform
CategoryClinical Research Platform
Description

Sequential's core platform delivers end-to-end clinical research for skin, scalp, intimate, and oral care, combining human clinical testing, biomarker discovery, and next-generation formulations powered by a multi-omics platform. The platform integrates study design, participant recruitment, non-invasive sample collection, in-house laboratory analysis, and claim-ready reporting for consumer goods, biotech, and pharmaceutical companies.

2Microbiome Testing
CategoryMicrobiome Analysis Service
Description

In-vivo microbiome testing service that quantifies the impact of raw materials and products on the skin microbiome and host-derived biomarkers, measuring 20 key microbes and providing full reports on microbiome balance for personal care and pharmaceutical companies.

3Multi-Omic Studies
CategoryMulti-Omics Analysis Service
Description

Comprehensive analysis combining microbiome sequencing, host genomic analysis, multi-omics technologies, and biophysical assessments to deliver a complete molecular picture of skin health and product impact for consumer goods and pharmaceutical clients.

4Clinical Assessments
CategoryClinical Assessment Service
Description

Biophysical testing add-ons including hydration measurement (corneometry and TEWL), elasticity measurement (elastometer), skin pH measurement, high-resolution imaging, dermatologist assessment (SCORAD, PASI), and perception questionnaires to supplement clinical studies.

5Ingredient Testing Services
CategoryIngredient Validation Service
Description

Clinical testing service for ingredient manufacturers that evaluates active ingredients within controlled base formulations, assessing biological impact through active vs. control comparison and dose-response evaluation to generate claim-ready evidence.

6Targeted Microbiome Panels
CategoryTargeted Diagnostic Panel
Description

Condition-specific microbiome target panels including the Sun/UV Targeted Panel featuring 23 Smart Probes for analyzing UV-exposed microbiota and skin conditions. Uses qPCR Smart Probes technology for absolute quantification of key microbial markers.

7White-Label Consumer Testing Kits
CategoryWhite-Label Consumer Product
Description

White-label at-home skin microbiome testing kits for commercial partners to offer end-consumers at-home skin microbiome testing with full reporting and personalization under their own brand.

8Biome Mask
CategoryConsumer Skincare Product
Description

Biodegradable sheet mask line with five formulas targeting different skin traits, infused with prebiotic and postbiotic serums. Made from semi-gel Tencel (100% cellulose), tested in-vivo. Designed to maintain the skin microbiome while targeting dehydration and sensitivity.

9AI-Powered Discovery Engine
CategoryAI Discovery Platform
Description

AI-powered discovery platform leveraging Sequential's clinical dataset of 50,000+ skin microbiome samples, 4,000+ ingredients, and 10,000+ participants to predict, optimize, and discover next-generation active ingredient complexes for skin health using computational modeling and systems biology.

10Maintains the Microbiome Certification
CategoryProduct Certification Program
Description

Certification program for products tested in-vivo using qPCR Smart Probes, awarding a 'Maintains the Microbiome' certification seal backed by quantifiable data and scientifically significant markers for use in marketing communications.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1J&J JLABS
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Sequential is a resident company at JLABS Innovation NYC, Johnson & Johnson's life sciences incubator. This partnership provides access to the J&J ecosystem, mentorship, and networking opportunities within the pharmaceutical and medical device industry.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Sequential entered a collaboration agreement with Johnson & Johnson for genomic-based skin test development, leveraging the company's multi-omics platform for pharmaceutical applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AMILI is a partner in Sequential's UK-Singapore R&D project, collaborating on microbiome research and development initiatives that span both regions.

4Gallinée
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Gallinée partnered with Sequential for at-home skin microbiome test kits, enabling the dermocosmetics brand to offer consumer-facing microbiome analysis services under their own brand through white-label arrangement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Belgium-based skin microbiome company developing live bacterial therapeutics and skin microbiome diagnostics for acne and other skin conditions. Direct peer as both companies focus on commercializing skin microbiome science for personal care and clinical applications.

TypeDirect peer
Description

Microbiome sequencing and bioinformatics services company serving consumer goods, clinical research, and industrial customers. Direct peer given overlap in microbial identification, bioinformatics, and B2B services to dermocosmetics and pharma clients.

3Second Genome
TypeEmerging player
Description

Microbiome drug discovery company with both therapeutic and microbiome analytics capabilities. Comparable in applying microbiome science to pharma and consumer health, though more therapeutics-focused than Sequential's testing-services model.

TypeDirect peer
Description

Testing services provider for the cosmetics, personal care, and medical device industries, offering clinical efficacy and safety testing. Direct peer as both serve dermocosmetics brands with clinical testing for product claims and regulatory support.

TypeBroad incumbent
Description

Large, established CRO offering clinical and preclinical testing services to pharma, biotech, and consumer health companies. Broad incumbent that competes for the same enterprise testing budgets Sequential targets, though not specialized in microbiome science.

TypeBroad incumbent
Description

Global testing services group with deep footprint in cosmetics, personal care, and pharma testing including microbiome analysis capabilities. Broad incumbent offering comparable end-to-end analytical services with significant scale advantage.

TypeEmerging player
Description

Microbiome-focused life sciences company providing sample collection devices, DNA extraction kits, and microbiome analysis services. Comparable in the microbiome tooling and services value chain, though more product-focused than Sequential's service-led model.

TypeDirect peer
Description

Skin testing laboratory providing clinical testing services for cosmetics, personal care, and dermatology products. Direct peer given overlap in skin-focused clinical testing services for product development and claim substantiation.

9Phylagen
TypeEmerging player
Description

Microbiome data analytics company using environmental and human microbiome sequencing for product and facility applications. Comparable as a microbiome analytics platform applying large datasets and bioinformatics to commercial use cases.

TypeEmerging player
Description

Microbiome-focused biotech combining synthetic biology with microbiome analytics for therapeutic and consumer applications. Comparable given overlap in microbiome science applied to skin and consumer health, though more therapeutics-oriented.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SEQUENTIAL

Microbiome Testing & Clinical Research Servicessequential.bio

Sequential is a London-based skin microbiome testing company that provides B2B multi-omics clinical research services, including microbiome sequencing, qPCR Smart Probes, and bioinformatics, to dermocosmetics brands, pharmaceutical companies, CROs, and ingredient manufacturers across the UK, US, and Singapore.

What SEQUENTIAL does

Sequential (legally Sequential Skin Ltd) is a London-headquartered skin microbiome testing company founded in 2019 that operates end-to-end clinical research services for the dermocosmetics, pharmaceutical, clinical research organization (CRO), and ingredient manufacturing industries. The company's core offering is a multi-omics platform combining microbiome sequencing (16S, ITS, shotgun metagenomics), proprietary qPCR Smart Probes, and bioinformatics to characterize the impact of skincare and therapeutic products on the human skin microbiome in vivo, supported by a proprietary database of 50,000+ skin microbiome samples linked to 4,000+ ingredient interactions and a non-invasive patch-based sample collection system (Sequential Patch). Modular add-ons include biophysical clinical assessments, condition-specific targeted panels (e.g., Sun/UV Panel), ingredient testing, participant recruitment, and white-label consumer test kits for commercial partners.

The business generates revenue primarily through professional services B2B contracts for clinical studies, supplemented by hardware/white-label consumer test kit partnerships (e.g., Gallinée) and consumer product lines such as the Biome Mask. Pricing is quote-based and not publicly disclosed, reflecting enterprise sales motion targeting large dermocosmetics brands, pharma therapeutics developers, CROs, and ingredient suppliers. The company operates labs in Cambridge (UK), New York City (US, via J&J JLABS Innovation NYC residency), and Singapore (supported by A*STAR and Enterprise Singapore), giving it a tri-regional UK-US-APAC footprint. Named commercial partners include Johnson & Johnson, Curive Healthcare, Gallinée, and Symbiome, with 100+ industry partners and 10,000+ study participants cumulatively enrolled across clinical studies. Sequential has raised approximately $7.5M in cumulative equity and grant funding, including a $1.65M seed round (October 2021), Innovate UK and A*STAR grants, a $1.8M UK-Singapore R&D grant (February 2025), and a $3.5M equity round (March 2026) co-led by Corundum Systems Biology and Sparkfood, with the most recent capital earmarked for an AI-Powered Discovery Engine launched alongside the financing.

SEQUENTIAL firmographics

Firmographics
Name
SEQUENTIAL
Legal name
Sequential Skin Ltd
Website
https://sequential.bio
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Sequential is a London-based skin microbiome testing company that provides B2B multi-omics clinical research services, including microbiome sequencing, qPCR Smart Probes, and bioinformatics, to dermocosmetics brands, pharmaceutical companies, CROs, and ingredient manufacturers across the UK, US, and Singapore.
Ownership category
akta.pro rank

SEQUENTIAL industry classification

Industry
Product category
Microbiome Testing & Clinical Research Services
NAICS
Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare

Keywords

  • Skin microbiome testing
  • Clinical research services
  • Multi-omics analysis
  • Dermatology clinical trials
  • Ingredient validation testing

Where SEQUENTIAL is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

SEQUENTIAL business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. B2B Clinical Testing Services: Sequential generates revenue primarily through providing contract clinical testing services to dermocosmetics brands, pharmaceutical companies, CROs, and ingredient manufacturers. Services include microbiome analysis, biomarker testing, and multi-omics characterization of skin health outcomes from product usage in human clinical studies.
  2. White-Label Consumer Testing Kits: Sequential offers white-label at-home skin microbiome test kits to commercial partners, enabling brands to provide direct-to-consumer microbiome analysis services under their own brand.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

SEQUENTIAL product offering

Product offering

Core offering

Sequential (operating as Sequential Skin Ltd) provides end-to-end in-vivo clinical testing and multi-omics analysis services for the personal care, pharmaceutical, and clinical research industries, specializing in skin microbiome characterization. The company integrates study design, participant recruitment, non-invasive sample collection, laboratory analysis (microbiome sequencing, qPCR, genomics, proteomics), and claim-ready reporting for dermocosmetics brands, pharma therapeutics developers, CROs, and ingredient manufacturers.

Product overview

Sequential operates a unified end-to-end clinical research platform for skin, scalp, oral, and intimate care, combining human in-vivo testing with a multi-omics analysis engine to quantify product and ingredient impact on skin and the microbiome. The platform is organized as a core testing platform supported by modular services: Microbiome Testing and Multi-Omic Studies form the analytical foundation, Clinical Assessments and Biophysical Measurements serve as add-on testing modules, Ingredient Testing Services and Targeted Microbiome Panels (including the Sun/UV Panel with Smart Probes qPCR) extend to specific use cases, and Consumer Kits and the Skin Health Tracker App address the direct-to-consumer segment. The Biome Mask is a separate consumer product line. The company also announced an AI-Powered Discovery Engine (March 2026) leveraging 50,000+ samples and 4,000+ ingredients to power predictive ingredient discovery. Labs are located in Cambridge, New York City, and Singapore.

Differentiator

Problem solved

Functional benefit

Brands

  • Sequential Bio: The company's testing and discovery platform serving consumer goods, biotech, and pharmaceutical companies for skin microbiome analysis.
  • Sequential Patch
  • Biome Mask
  • Smart Probes
  • Skin Tracker App

Products and services

  • Sequential End-to-End Clinical Testing Platform Sequential's core platform delivers end-to-end clinical research for skin, scalp, intimate, and oral care, combining human clinical testing, biomarker discovery, and next-generation formulations powered by a multi-omics platform. The platform integrates study design, participant recruitment, non-invasive sample collection, in-house laboratory analysis, and claim-ready reporting for consumer goods, biotech, and pharmaceutical companies.
  • Microbiome Testing In-vivo microbiome testing service that quantifies the impact of raw materials and products on the skin microbiome and host-derived biomarkers, measuring 20 key microbes and providing full reports on microbiome balance for personal care and pharmaceutical companies.
  • Multi-Omic Studies Comprehensive analysis combining microbiome sequencing, host genomic analysis, multi-omics technologies, and biophysical assessments to deliver a complete molecular picture of skin health and product impact for consumer goods and pharmaceutical clients.
  • Clinical Assessments Biophysical testing add-ons including hydration measurement (corneometry and TEWL), elasticity measurement (elastometer), skin pH measurement, high-resolution imaging, dermatologist assessment (SCORAD, PASI), and perception questionnaires to supplement clinical studies.
  • Ingredient Testing Services Clinical testing service for ingredient manufacturers that evaluates active ingredients within controlled base formulations, assessing biological impact through active vs. control comparison and dose-response evaluation to generate claim-ready evidence.
  • Targeted Microbiome Panels Condition-specific microbiome target panels including the Sun/UV Targeted Panel featuring 23 Smart Probes for analyzing UV-exposed microbiota and skin conditions. Uses qPCR Smart Probes technology for absolute quantification of key microbial markers.
  • White-Label Consumer Testing Kits White-label at-home skin microbiome testing kits for commercial partners to offer end-consumers at-home skin microbiome testing with full reporting and personalization under their own brand.
  • Biome Mask Biodegradable sheet mask line with five formulas targeting different skin traits, infused with prebiotic and postbiotic serums. Made from semi-gel Tencel (100% cellulose), tested in-vivo. Designed to maintain the skin microbiome while targeting dehydration and sensitivity.
  • AI-Powered Discovery Engine AI-powered discovery platform leveraging Sequential's clinical dataset of 50,000+ skin microbiome samples, 4,000+ ingredients, and 10,000+ participants to predict, optimize, and discover next-generation active ingredient complexes for skin health using computational modeling and systems biology.
  • Maintains the Microbiome Certification Certification program for products tested in-vivo using qPCR Smart Probes, awarding a 'Maintains the Microbiome' certification seal backed by quantifiable data and scientifically significant markers for use in marketing communications.

Quantifiable outcome

  • Database of 50,000+ skin microbiome samples
  • +3 more outcomes

Companies that use SEQUENTIAL

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles4 records

SEQUENTIAL technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

SEQUENTIAL partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and core.

  • J&J JLABSmajorStrategic or Co-development Partner · 1 January 2024Sequential is a resident company at JLABS Innovation NYC, Johnson & Johnson's life sciences incubator. This partnership provides access to the J&J ecosystem, mentorship, and networking opportunities within the pharmaceutical and medical device industry.
  • Johnson & JohnsonmajorStrategic or Co-development Partner · 1 January 2024Sequential entered a collaboration agreement with Johnson & Johnson for genomic-based skin test development, leveraging the company's multi-omics platform for pharmaceutical applications.
  • AMILIcoreStrategic or Co-development PartnerAMILI is a partner in Sequential's UK-Singapore R&D project, collaborating on microbiome research and development initiatives that span both regions.
  • GallinéecoreOEM/ Whitelabel/ Licensing PartnerGallinée partnered with Sequential for at-home skin microbiome test kits, enabling the dermocosmetics brand to offer consumer-facing microbiome analysis services under their own brand through white-label arrangement.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

SEQUENTIAL competitors and assessment

Company assessment

Direct peers

  • S-Biomedic: Belgium-based skin microbiome company developing live bacterial therapeutics and skin microbiome diagnostics for acne and other skin conditions. Direct peer as both companies focus on commercializing skin microbiome science for personal care and clinical applications.
  • CosmosID: Microbiome sequencing and bioinformatics services company serving consumer goods, clinical research, and industrial customers. Direct peer given overlap in microbial identification, bioinformatics, and B2B services to dermocosmetics and pharma clients.
  • Complife Group: Testing services provider for the cosmetics, personal care, and medical device industries, offering clinical efficacy and safety testing. Direct peer as both serve dermocosmetics brands with clinical testing for product claims and regulatory support.
  • Labskin (RISE)': Skin testing laboratory providing clinical testing services for cosmetics, personal care, and dermatology products. Direct peer given overlap in skin-focused clinical testing services for product development and claim substantiation.

Emerging players

  • Second Genome: Microbiome drug discovery company with both therapeutic and microbiome analytics capabilities. Comparable in applying microbiome science to pharma and consumer health, though more therapeutics-focused than Sequential's testing-services model.
  • Zymo Research: Microbiome-focused life sciences company providing sample collection devices, DNA extraction kits, and microbiome analysis services. Comparable in the microbiome tooling and services value chain, though more product-focused than Sequential's service-led model.
  • Phylagen: Microbiome data analytics company using environmental and human microbiome sequencing for product and facility applications. Comparable as a microbiome analytics platform applying large datasets and bioinformatics to commercial use cases.
  • Eligo Bioscience: Microbiome-focused biotech combining synthetic biology with microbiome analytics for therapeutic and consumer applications. Comparable given overlap in microbiome science applied to skin and consumer health, though more therapeutics-oriented.

Broad incumbents

  • Charles River Laboratories: Large, established CRO offering clinical and preclinical testing services to pharma, biotech, and consumer health companies. Broad incumbent that competes for the same enterprise testing budgets Sequential targets, though not specialized in microbiome science.
  • Eurofins Scientific: Global testing services group with deep footprint in cosmetics, personal care, and pharma testing including microbiome analysis capabilities. Broad incumbent offering comparable end-to-end analytical services with significant scale advantage.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

SEQUENTIAL social profiles

Digital presence

SEQUENTIAL compliance and trust

Trust signal

Compliance1 record

SEQUENTIAL financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SEQUENTIAL leadership team

Management profile

Number of profiles

Profiles7 records

SEQUENTIAL funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SEQUENTIAL M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SEQUENTIAL

What does SEQUENTIAL do?

Sequential (operating as Sequential Skin Ltd) provides end-to-end in-vivo clinical testing and multi-omics analysis services for the personal care, pharmaceutical, and clinical research industries, specializing in skin microbiome characterization. The company integrates study design, participant recruitment, non-invasive sample collection, laboratory analysis (microbiome sequencing, qPCR, genomics, proteomics), and claim-ready reporting for dermocosmetics brands, pharma therapeutics developers, CROs, and ingredient manufacturers.

Is SEQUENTIAL a public or private company?

SEQUENTIAL is a private company. It is classified as venture growth investor backed and is currently operating.

When was SEQUENTIAL founded?

SEQUENTIAL was founded in 2019. It employs 11 to 50 people.

Where is SEQUENTIAL based?

SEQUENTIAL is headquartered in London, United Kingdom, in the Europe region.

How does SEQUENTIAL make money?

Two revenue lines are on record. B2B Clinical Testing Services are the primary driver. The others are white-Label Consumer Testing Kits.

Who are SEQUENTIAL's main competitors?

Direct peers on record are S-Biomedic, CosmosID, Complife Group and Labskin (RISE)'. Emerging players are Second Genome, Zymo Research, Phylagen and Eligo Bioscience. Broad incumbents are Charles River Laboratories and Eurofins Scientific.

Does SEQUENTIAL have an API?

No public API is recorded for SEQUENTIAL.

What industry is SEQUENTIAL in?

SEQUENTIAL's product category is Microbiome Testing & Clinical Research Services. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAAANAI, Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials). Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSequential Announces Inaugural London Conference on Next-Generation Ingredients, Uniting AI Discovery and Clinical ValidationSequential announced its first industry conference, The Future of Next-Generation Ingredients & Validation, on 3 December 2026 in London. The one-day forum will bring together R&D and scientific leaders to discuss AI and multi-omics in ingredient discovery and clinical validation. Seven speakers are confirmed, including a keynote by Lieve Declercq of Proya Companies.PR NewswireSequential Announces Inaugural London Conference on Next-Generation Ingredients, Uniting AI Discovery and Clinical ValidationSequential announced its first industry conference, The Future of Next-Generation Ingredients & Validation, on 3 December 2026 in London. The one-day forum brings together R&D and scientific leaders to discuss AI and multi-omics in ingredient discovery and clinical validation. Seven speakers are confirmed, including a keynote by Lieve Declercq of Proya Companies.PR NewswireSequential Announces Inaugural London Conference on Next-Generation Ingredients, Uniting AI Discovery and Clinical ValidationSequential announced its first industry conference, The Future of Next-Generation Ingredients & Validation, on 3 December 2026 in London. The one-day forum will bring together R&D and scientific leaders to discuss AI and multi-omics in ingredient discovery and clinical validation. Seven speakers are confirmed, including a keynote by Lieve Declercq of Proya Companies.ThebridgeSequential Raises ¥5.5 Billion for Skin Microbiome Analysis—Led by Corundum Systems BiologySequential, a provider of a platform integrating skin microbiome and molecular data for ingredient and product impact quantification, announced on the 25th that it raised approximately $3.5 million (about ¥5.5 billion) in its initial equity round. The funding was co-led by Corundum Systems Biology and Sparkfood, with participation from SOSV, Scrum Ventures, and continued support from Innovate UK, bringing total raised to approximately $7.5 million. The company plans to allocate the funds toward developing an AI-powered discovery engine based on its clinical data from over 50,000 samples and 4,000 ingredients.PrtimesRaised approximately 550 million yen in a sequential, colandrum system biology-led funding round.Sequential has completed its first equity funding round, raising approximately 3.5 million USD (about 550 million yen), co-led by Corundum System Biology and Sparkfood, with participation from SOSV and Scrum Ventures and continued support from Innovate UK, bringing total funding to approximately 7.5 million USD. The company operates a non-invasive testing platform that quantifies the impact of raw materials and products on skin microbiome and host-derived biomarkers, with over 50,000 samples from more than 10,000 subjects and data on over 4,000 ingredients. The funds will be used to develop an AI-powered discovery engine based on the company's real-world clinical data to accelerate the prediction, optimization, and discovery of next-generation active ingredient complexes.Longevity.TechnologySequential banks $3.5m for smarter skin healthSequential, a Cambridge-based skin health testing company, raised $3.5 million in its first equity round, bringing its total funding to $7.5 million. The company uses non-invasive testing to measure microbial signals and host biomarkers to validate product effects on skin and its ecosystem, aiming to build an AI-powered discovery engine based on a large clinical dataset.BebeezSequential™ Raises $3.5M to Build AI-Powered Discovery Platform for Multi-Omic Testing and Next-Generation Skin Health Ingredients – BeBeez InternationalSequential, a Cambridge-based genomic testing company specializing in skin microbiome analysis, announced the close of its first equity round raising $3.5 million, co-led by Sparkfood and Corundum Systems Biology with participation from Dermazone Holdings, SOSV, and Scrum Ventures. The funding will support development of an AI-powered discovery engine built on the company's proprietary clinical dataset of over 50,000 samples, 4,000+ ingredients, and 10,000+ participants to predict and discover next-generation bioactive skin health ingredients. Sequential has now secured a total of $7.5 million in dilutive and non-dilutive funding to date, backed by Innovate UK and Enterprise Singapore.PR NewswireSequential™ lève 3,5 millions de dollars pour construire une plateforme de découverte alimentée par l'IA pour les tests multi-omiques et les ingrédients de nouvelle génération pour la santé de la peauSequential, a leader in genomic testing from non-invasive clinical human samples, announced the closing of its first funding round at $3.5 million, co-led by Sparkfood and Corundum Systems Biology with participation from Dermazone Holdings, SOSV, Scrum Ventures, and continued support from Innovate UK, bringing its total dilutive and non-dilutive funding to $7.5 million. The capital will fund the development of an AI-powered discovery engine built on Sequential's proprietary real-world clinical dataset of over 50,000 samples, 4,000 ingredients, and 10,000 participants worldwide, enabling the prediction and discovery of next-generation active complexes and bioactive ingredients for skin health. The company operates labs in Cambridge, New York City, and Singapore and aims to establish a new standard for data-driven innovation in personal care and adjacent health categories.Pulse 2.0Sequential: $3.5 Million Raised By Skin Microbiome Testing Company For AI-Powered Discovery PlatformSequential, a genomic testing company specializing in skin microbiome analysis, announced it raised $3.5 million in its first equity funding round, bringing its total funding to $7.5 million, with the round co-led by Sparkfood and Corundum Systems Biology alongside participation from Dermazone Holdings, SOSV, Scrum Ventures, and others. The funding will be used to develop an AI-powered discovery engine leveraging the company's proprietary platform that has built a clinical dataset of more than 50,000 samples, over 4,000 ingredients, and participation from more than 10,000 individuals globally. The company operates labs in Cambridge, New York City, and Singapore, with research applications targeting inflammatory skin conditions such as acne, atopic dermatitis, and rosacea.PR NewswireSequential™ Raises $3.5M to Build AI-Powered Discovery Platform for Multi-Omic Testing and Next-Generation Skin Health IngredientsSequential, a Cambridge-based genomic testing company specializing in skin microbiome analysis, announced the close of its first equity round raising $3.5 million, co-led by Sparkfood and Corundum Systems Biology with participation from Dermazone Holdings, SOSV, Scrum Ventures, and an ex-General Partner at Index Ventures. The funding brings the company's total dilutive and non-dilutive financing to $7.5 million and will be used to develop an AI-powered discovery engine built on Sequential's proprietary dataset of over 50,000 skin microbiome samples, 4,000+ ingredients, and 10,000+ participants. The company aims to leverage this clinical dataset to predict, optimize, and discover next-generation active complexes and novel bioactive ingredients for the personal care industry.